Although anti-angiogenic therapies targeting vascular endothelial growth factor (VEGF) can increase cancer patient survival, many tumors activate angiogenesis via multiple signalling pathways and mediators, and may become refractory to anti-VEGF therapy. This evidence concerns the gene VEGFA and cancer.